Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Fmr LLC

Fmr LLC grew its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 5.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,339,522 shares of the company’s stock after buying an additional 111,104 shares during the period. Fmr LLC’s holdings in Intellia Therapeutics were worth $48,077,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of NTLA. Comerica Bank lifted its stake in Intellia Therapeutics by 853.6% in the 1st quarter. Comerica Bank now owns 37,105 shares of the company’s stock worth $1,021,000 after purchasing an additional 33,214 shares in the last quarter. GAMMA Investing LLC lifted its position in Intellia Therapeutics by 1,322.0% during the second quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock worth $59,000 after buying an additional 2,459 shares in the last quarter. AdvisorNet Financial Inc boosted its stake in Intellia Therapeutics by 63.5% during the second quarter. AdvisorNet Financial Inc now owns 5,100 shares of the company’s stock worth $114,000 after buying an additional 1,980 shares during the last quarter. Blue Trust Inc. grew its holdings in Intellia Therapeutics by 1,664.3% in the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after buying an additional 1,398 shares in the last quarter. Finally, Intellectus Partners LLC increased its stake in shares of Intellia Therapeutics by 2.1% in the 2nd quarter. Intellectus Partners LLC now owns 58,225 shares of the company’s stock worth $1,303,000 after acquiring an additional 1,225 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on NTLA shares. Barclays reduced their target price on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Wells Fargo & Company decreased their price objective on Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating on the stock in a report on Monday, November 18th. JPMorgan Chase & Co. cut their target price on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Wedbush restated a “neutral” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a research report on Monday, November 18th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $54.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, September 19th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $54.94.

Insiders Place Their Bets

In other news, CAO Michael P. Dube sold 2,012 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. The trade was a 4.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.20% of the stock is currently owned by company insiders.

Intellia Therapeutics Trading Up 7.8 %

NASDAQ:NTLA opened at $14.72 on Friday. Intellia Therapeutics, Inc. has a 12-month low of $12.82 and a 12-month high of $34.87. The firm has a market cap of $1.50 billion, a PE ratio of -2.71 and a beta of 1.76. The stock has a fifty day moving average price of $16.61 and a 200 day moving average price of $20.98.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $8.28 million. During the same quarter in the previous year, the business posted ($1.38) EPS. The business’s quarterly revenue was down 24.1% compared to the same quarter last year. Equities analysts forecast that Intellia Therapeutics, Inc. will post -5.12 EPS for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.